ClinicalTrials.gg
CompletedNCT05371899Updated Jul 15, 2024

Mass Balance Study of [14C]Chiauranib

An interventional study of Chiauranib in Small Cell Lung Cancer, sponsored by Chipscreen Biosciences, Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-07-15.

Sponsored by Chipscreen Biosciences, Ltd. · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 365 studies in Small Cell Lung Carcinoma with a site in China — 183 open to participants now, 215 under way, 36 of them phase 3. Small Cell Lung Carcinoma · China.

Enrollment
329th of 333
6 · median 63
Started
2022
with 17 others
No phase
26 of 365
15 open now
Registered
158th of 365
by date

Among the 365 studies in Small Cell Lung Carcinoma with a site in China, this one is the 329th largest by enrollment of the 333 interventional ones that give a count, is one of 18 that started in 2022, is one of 26 with no phase, and was the 158th registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

183 of the 365 studies in Small Cell Lung Carcinoma with a site in China are open now. Recruiting first, the newest first:

178 more — sign in →

All 183 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 365 studies in Small Cell Lung Carcinoma with a site in China, or all of them as a file.
02

Study summary

Chiauranib , which simultaneously targets against VEGFR/Aurora B/CSF-1R, several key kinases involved in tumor angiogenesis, tumor cell mitosis, and chronic inflammatory microenvironment.

Read the detailed description

Chiauranib , which simultaneously targets against VEGFR/Aurora B/CSF-1R, several key kinases involved in tumor angiogenesis, tumor cell mitosis, and chronic inflammatory microenvironment.

Chiauranib is a novel orally active multi-target inhibitor that simultaneously inhibits the angiogenesis-related kinases (VEGFR2, VEGFR1, VEGFR3, PDGFRa and c-Kit), mitosis-related kinase Aurora B and chronic inflammationrelated kinase CSF-1R in a high potency manner with the IC50 at a single-digit nanomolar range. In particular, Chiauranib showed very high selectivity in the kinase inhibition profile with little activity on off-target non-receptor kinases, proteins, GPCR and ion channels, indicative of a better drug safety profile in terms of clinical relevance.

This trial is a material balance study of [14C]Chiauranib in participants with small cell lung cancer, with the goal of learning more about the drug's absorption, metabolism, and excretion in the human body, as well as monitoring the subjects' safety after treatment. Chiauranib's scientific foundation for future progress.

03

Conditions studied

  • Small Cell Lung Cancer

Keywords

  • Chiauranib
  • pharmacokinetic characteristics
  • Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ages: 18 Years to 75 Years
  • or histologically confirmed small cell lung cancer
  • After normal therapy, disease progression or returnrecurrence
  • (ECOG) Performance Status of 0 or 1
  • of at least 3 months
  • Laboratory criteria are as follows:

    • Complete blood count: (ANC) ≥1.5×10\^9/L ; ≥75×10\^9/L; (Hb) ≥80g/L ;
    • Biochemistry test: total ≤1.5×; (ALT) , aspartate aminotransferase(AST)≤2.5×ULN(ALT,AST≦5×ULN if liver involved); serum creatinine(cr)≤1.5×ULN;
    • Coagulation test: (INR) \< 1.5.
  • All patients must have given signed, prior to registration on study

Exclusion criteria

Exclusion Criteria:

  • Patients experiencing neurological symptoms due to liver or
  • Patients with hemoptysis or tumor invading around important blood vessels and hemoptysis during the screening period
  • Pleural fluid, ascites, pericardial effusion with clinical symptoms and need to be drained during the screening period
  • Patients with second primary cancer, except: adequately treated basal cell or squamous cell skin cancer, curatively treated in-situ cancer of the cervix, unless received curative treatment and with documented evidence of no recurrence during the past five years
  • Sunitinib, bevacizumab, anlotinib, apatinib, endostat, and other Aurora kinase inhibitors or VEGF/VEGFR inhibitors were used to treat this small cell lung cancer
  • Patients have used any anti-cancer therapy, including, chemotherapy, immunotherapy, target therapy, and other anti-tumor treatments within 14 days before the first dose, Patients have used adiotherapy within 14 days before the first dose
  • Patients received major surgical operations within 28 days before the first dose, or patients with serious non-healing wounds, ulcer or fracture at the time of screening
  • With the exception of alopecia, any ongoing toxicities (> grade 1) caused by previous cancer therapy
  • Abnormal and ophthalmic examination
  • Patients with uncontrolled or significant cardiovascular disease, including:

    • Grade II or higher Congestive heart failure, unstable angina pectoris, myocardial infarction ( Classification) within 6 months prior to study entry; or arrhythmia requiring treatment, or (LVEF) \< 50% during screening stage.
    • Primary cardiomyopathy (dilated cardiomyopathy, hypertrophic cardiomyocyte, arrhythmogenic right ventricular cardiomyopathy, restrictive cardiomyopathy, et,al).
    • History of significant prolongation, or Corrected QT Interval QTc≥450ms(male),QTc≥470ms(female)at screening.
    • patient's treatment record of using at least 2 antihypertensive drugs at the same Within 14 days before the first dose, or uncontrolled hypertension (> 140/90 mmHg) during the screening period.
  • Lung disease that seriously affects ventilation or diffusing function during the screening period
  • Patients with factors that could affect oral medication (such as dysphagia,chronic diarrhea, intestinal obstruction, After small bowel resection,etc), or undergone gastrectomy, or history of gastrointestinal perforation
  • Unhealed diarrhea prior to dosing, or 4 or more episodes of diarrhea within 7 days prior to planned dosing, or habitual diarrhea
  • Habitual constipation persists after treatment
  • During the screening period, when the urine protein in the routine urine test is ≥2+, a 24-hour urine protein quantitative test should be carried out. Protein ≥2+, quantitative examination \<1g/24h can be enrolled
  • Active bleeding within 2 months before the first dose, or anticoagulant drugs are being taken during the screening period, or the investigator judges that there is a high risk of bleeding during the screening period
  • History of deep vein thrombosis or pulmonary embolism within 6 months before the first dose
  • Active infections that require systemic treatment (oral, intravenous infusion) during the screening period
  • With clinically significant UTI or genital infection, or with a history of complicated UTI
  • Positive for any one of surface antigen, hepatitis B e antigen, antibody, antibody, syphilis antibody and new crown screening
  • Any mental or cognitive disorder, that would impair the ability to understand the document, or the compliance of study
  • Allergic to cioroni capsules and its
  • Subjects who have taken any drugs known to induce or inhibit hepatic drug metabolism(, CYP1A2 and CYP2D6)within 30 days prior to drug administration of the study medication
  • Any other condition which is inappropriate for the study according to investigators' judgment
  • Binge drinking or drinking greater than 14 units of alcohol per week in the 6 months prior to screening; or alcohol breath test results ≥ 20 mg/dl during the screening period
  • Smoking more than 5 cigarettes per day or habitual use of nicotine-containing products within 2 months before screening, or unable to quit during the trial
  • Habitual consumption of grapefruit juice or excessive tea, coffee and/or caffeinated beverages and inability to withdraw during the trial
  • Drug abuse or drug abuse that affects the evaluation of test results, or a positive urine drug test during the screening period
  • Women of not willing to use and utilize an adequate method of (such as intrauterine device, contraceptive and condom) throughout treatment and for at least 12 weeks after the last dose; pregnant or breastfeeding women; the result of urine pregnancy test was positive at screening; Man participants not willing to use and utilize an adequate method of contraception throughout treatment
  • Engaged in work requiring prolonged exposure to radioactive conditions; or participated in radiopharmaceutical labeling experiments
  • Difficulty of venous blood collection
  • Volunteer in any other study within 3 months prior to drug administration, or Volunteer in 3 times or more studies
  • Blood donation or lost more than 400mL blood within 3 months prior to the study, or Received blood transfusions within 1 month
  • Other situations that the researchers considered unsuitable to enroll the subject
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Other
    Chiauranib

    Take 50 mg ChiauranibCioroni capsules orally on an empty stomach once a day, every day; except on the eighth day 8, when you start taking Cioroni capsules liquid, take a single oral dose of \~50 mg/about 100 Ci of \[14C\]Chiauranib suspensionCioroni solution once on an empty stomach.

    Drug: Chiauranib

Interventions

  • Take Chiauranib 50mg orally once daily

06

What researchers measure

Primary outcomes

  1. Tmax

    Time to maximum concentration

    Time frame: The sample collection for the last subject was done, and the safety inspection was performed,assessed up to 22 days

  2. Cmax

    Maximum concentration

    Time frame: The sample collection for the last subject was done, and the safety inspection was performed,assessed up to 22 days

  3. AUC

    Area under the plasma concentration-time curve

    Time frame: The sample collection for the last subject was done, and the safety inspection was performed,assessed up to 22 days

  4. t1/2

    Half life

    Time frame: The sample collection for the last subject was done, and the safety inspection was performed,assessed up to 22 days

  5. MRT

    Mean resident time

    Time frame: The sample collection for the last subject was done, and the safety inspection was performed,assessed up to 22 days

  6. Whole blood/plasma concentration (B/P) ratios for total radioactivity

    Whole blood/plasma concentration (B/P) ratios for total radioactivity

    Time frame: The sample collection for the last subject was done, and the safety inspection was performed,assessed up to 22 days

  7. Cumulative amount of radioactivity recovered in urine, feces, and in total

    Cumulative amount of radioactivity recovered in urine, feces, and in total

    Time frame: The sample collection for the last subject was done, and the safety inspection was performed,assessed up to 22 days

  8. Percent of Metabolite in plasma, urine and feces

    Percent of Metabolite in plasma, urine and feces

    Time frame: The sample collection for the last subject was done, and the safety inspection was performed,assessed up to 22 days

Secondary outcomes

  1. percentage of AEs

    Safety

    Time frame: The sample collection for the last subject was done, and the safety inspection was performed,assessed up to 22 days

07

Study locations

1 site
  • The First Affiliated Hospital of Suzhou University
    Suzhou, Jiangsu 21500, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2022 to primary completion in Mar 2024, 19 months.

Of 47 interventional studies with no phase under Small Cell Lung Carcinoma, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 73. This study's 19 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2022
First posted
May 12, 2022
StartActual
Jul 20, 2022
Primary completionActual
Mar 18, 2024
CompletionActual
Mar 18, 2024
Last update
Jul 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05371899
Responsible party
Sponsor
First posted
May 12, 2022
Start date
Jul 20, 2022
Primary completion
Mar 18, 2024
Completion
Mar 18, 2024
Last update
Jul 15, 2024

Study contacts

Jianan Huang
principal investigator · The First Affiliated Hospital of Soochow University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Chiauranib

Start the discussion